The interplay of structure and dynamics: Insights from a survey of HIV-1 reverse transcriptase crystal structures

Proteins: Structure, Function and Bioinformatics

Volumn 81, Issue 10, 2013, Pages 1792-1801

  Seckler, James M ^a   Leioatts, Nicholas ^b   Miao, Hongyu ^a   Grossfield, Alan ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Allostery; Elastic network model; Protein drug interactions; Reverse transcriptase inhibition; Structure function

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE;

ARTICLE; COMPARATIVE STUDY; CONFORMATION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DYNAMICS; ENZYME STRUCTURE; HYDROPHOBICITY; MOLECULAR DYNAMICS; MUTANT; MUTATION; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLOSTERY; ELASTIC NETWORK MODEL; PROTEIN-DRUG INTERACTIONS; REVERSE TRANSCRIPTASE INHIBITION; STRUCTURE-FUNCTION;

CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; HIV REVERSE TRANSCRIPTASE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION;

EID: 84884204842     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24325     Document Type: Article

References (58)

1. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.
2. Boyer PL, Ferris AL, Clark P, Whitmer J, Frank P, Tantillo C, Arnold E, Hughes SH. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. J Mol Biol 1994;243:472-483.
3. Bahar I, Erman B, Jernigan RL, Atilgan AR, Covell DG. Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. J Mol Biol 1999;285:1023-1037.
4. Seckler JM, Barkley MD, Wintrode PL. Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding. Biophys J 2011;100:144-153.
5. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, Hao Z, Gerrard TL, Wilson YA, Johns DG, Broder S. Inhibition of human mmunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′, 3′-dideoxynucleosides. J Exp Med 1988;168:1111-1125.
6. Shaw-Reid CA, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ, Parniak MA, Miller MD, Lewis D. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 2005;44:1595-1606.
7. Hang JQ, Li Y, Yang Y, Cammack N, Mirzadegan T, Klumpp K. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun 2007;352:341-350.
8. Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol 2008;73:601-606.
9. Das K, Martinez SE, Bauman JD, Arnold E. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol 2012;19:253-259.
10. Ren J, Stammers DK. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 2008;134:157-170.
11. Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, McCoy-Simandle K, Ilina T, Clark AD, Jr, Knight JL, Julias JG, Clark PK, Krogh-Jespersen K, Levy, RM, Hughes SH, Parniak MA, Arnold E. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol 2006;1:702-712.
12. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009;385:693-713.
13. Miller CD, Crain J, Tran B, Patel N. Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc) 2011;47:5-15.
14. Hsiou Y, Ding J, Das K, Clark AD, Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rosner M, Hughes SH, Arnold E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001;309:437-445.
15. Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Chan JH, Kleim JP, Stammers DK. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J Med Chem 2007;50:2301-2309.
16. Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers DK. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J Mol Biol 2004;336:569-578.
17. Sarafianos SG, Das K, Hughes SH, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol 2004;14:716-730.
18. Hsiou Y, Das K, Ding J, Clark AD, Jr, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH, Arnold, E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 1998;284:313-323.
19. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995;3:915-926.
20. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001;312:795-805.
21. O'Brien SE, Brown DG, Mills JE, Phillips C, Morris G. Computational tools for the analysis and visualization of multiple protein-ligand complexes. J Mol Graph Model 2005;24:186-194.
22. Paris KA, Haq O, Felts AK, Das K, Arnold E, Levy RM. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. J Med Chem 2009;52:6413-6420.
23. van Westen GJ, Wegner JK, Bender A, Ijzerman AP, van Vlijmen HW. Mining protein dynamics from sets of crystal structures using "consensus structures". Protein Sci 2010;19:742-752.
24. Grossfield A, Zuckerman DM. Quantifying uncertainty and sampling quality in biomolecular simulations. Annu Rep Comput Chem 2009;5:23-48.
25. Romo TD, Grossfield A. Validating and improving elastic network models with molecular dynamics simulations. Proteins 2011;79:23-34.
26. Atilgan AR, Durell SR, Jernigan RL, Demirel MC, Keskin O, Bahar I. Anisotropy of fluctuation dynamics of proteins with an elastic network model. Biophys J 2001;80:505-515.
27. Temiz NA, Meirovitch E, Bahar I. Escherichia coli adenylate kinase dynamics: comparison of elastic network model modes with mode-coupling (15)N-NMR relaxation data. Proteins 2004;57:468-480.
28. Deriu MA, Soncini M, Orsi M, Patel M, Essex JW, Montevecchi FM, Redaelli A. Anisotropic elastic network modeling of entire microtubules. Biophys J 2010;99:2190-2199.
29. Keskin O, Durell SR, Bahar I, Jernigan RL, Covell DG. Relating molecular flexibility to function: a case study of tubulin. Biophys J 2002;83:663-680.
30. Mao Y. Dynamical basis for drug resistance of HIV-1 protease. BMC Struct Biol 2011;11:31.
31. Wang Y, Rader AJ, Bahar I, Jernigan RL. Global ribosome motions revealed with elastic network model. J Struct Biol 2004;147:302-314.
32. Leioatts N, Romo TD, Grossfield A. Elastic network models are robust to variations in formalism. J Chem Theory Comput 2012;8:2424-2434.
33. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 1977;112:535-542.
34. Woodcock HL, Zheng W, Ghysels A, Shao Y, Kong J, Brooks BR. Vibrational subsystem analysis: a method for probing free energies and correlations in the harmonic limit. J Chem Phys 2008;129:214109.
35. Hess B. Convergence of sampling in protein simulations. Phys Rev E Stat Nonlin Soft Matter Phys 2002;65:031910.
36. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
37. Van Wynsberghe AW, Cui Q. Interpreting correlated motions using normal mode analysis. Structure 2006;14:1647-1653.
38. Fisher RA. Frequency distribution of the values of the correlation coefficient in samples of an indefinitely large population. Biometrika 1915;10:507-521.
39. Welch BL. The generalisation of student's problems when several different population variances are involved. Biometrika 1947;34:28-35.
40. Romo TD, Grossfield A. LOOS: an extensible platform for the structural analysis of simulations. Conf Proc IEEE Eng Med Biol Soc 2009;2009:2332-2335.
41. Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. AIDS Res Hum Retroviruses 2007;23:682-685.
42. Steitz TA. Visualizing polynucleotide polymerase machines at work. EMBO J 2006;25:3458-3468.
43. Svetlov V, Nudler E. Macromolecular micromovements: how RNA polymerase translocates. Curr Opin Struct Biol 2009;19:701-707.
44. Shen L, Shen J, Luo X, Cheng F, Xu Y, Chen K, Arnold E, Ding J, Jiang H. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys J 2003;84:3547-3563.
45. Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002;49:61-70.
46. Zhou Z, Madrid M, Evanseck JD, Madura JD. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. J Am Chem Soc 2005;127:17253-17260.
47. Chamberlain PP, Ren J, Nichols CE, Douglas L, Lennerstrand J, Larder BA, Stuart DI, Stammers DK. Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J Virol 2002;76:10015-10019.
48. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000;8:1089-1094.
49. Braz VA, Holladay LA, Barkley MD. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. Biochemistry 2010;49:601-610.
50. Wang J, Liang H, Bacheler L, Wu H, Deriziotis K, Demeter LM, Dykes C. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations. Virology 2010;402:228-237.
51. Das K, Clark AD, Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL Clark P, Hughes SH, Janssen PA, Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550-2560.
52. Das K, Ding J, Hsiou Y, Clark AD, Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH, Jr, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996;264:1085-1100.
53. Bakan A, Bahar I. The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding. Proc Natl Acad Sci USA 2009;106:14349-14354.
54. Hsiou Y, Ding J, Das K, Clark AD, Jr, Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996;4:853-860.
55. Sarafianos SG, Clark AD, Jr, Das K, Tuske S, Birktoft JJ, Ilankumaran P, Ramesha AR, Sayer JM, Jerina DM, Boyer PL, Hughes SH, Arnold E. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J 2002;21:6614-6624.
56. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995;2:303-308.
57. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995;2:293-302.
58. Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 2002;269:1670-1677.